by Sergi | Dec 15, 2025 | Press Releases
Amira Therapeutics’ Lead Compound AMI463 Demonstrates 60% Tumor Reduction in Preclinical Oral Study AMI463 has been tested in a murine model showing a tumor reduction of 60% compared with the control group. Amira is currently preparing a meeting with the AEMPS to...
by Sergi | Apr 9, 2024 | Press Releases
Amira Therapeutics Receives Orphan Drug Designation for AMI463 in Soft Tissue Sarcoma in the United States Amira therapeutics has received orphan drug designation (ODD) for its compound AMI463 by the FDA. The compound had previously received the designation of rare...
